Natera Temettü

Temettü kriter kontrolleri 0/6

Natera şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-1.7%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-1.7%
Gelecekteki Temettü Verimi	0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Natera And GeneDx: Outperforming Market Powered By Precision Medicines Tailwinds

Oct 31

Natera, Inc.'s (NASDAQ:NTRA) Intrinsic Value Is Potentially 20% Below Its Share Price

Sep 18

Does Natera (NASDAQ:NTRA) Have A Healthy Balance Sheet?

Jul 05

Natera: Overdue For A Breather

Jun 03

Natera, Inc. (NASDAQ:NTRA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$119

May 12

Natera, Inc. (NASDAQ:NTRA) Shares Could Be 46% Below Their Intrinsic Value Estimate

Aug 07

Health Check: How Prudently Does Natera (NASDAQ:NTRA) Use Debt?

May 16

Natera, Inc.'s (NASDAQ:NTRA) Low P/S No Reason For Excitement

Apr 18

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: NTRA şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: NTRA şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Natera Piyasaya Karşı Temettü Getirisi

NTRA temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (NTRA)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.5%
Sektör Ortalaması (Biotechs)	2.2%
Analist tahmini (NTRA) (3 yıla kadar)	0%

Önemli Temettü: NTRA şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, NTRA şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: NTRA şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: NTRA herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Natera Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

Natera, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Natera And GeneDx: Outperforming Market Powered By Precision Medicines Tailwinds

Now 22% overvalued after recent price rise

Co-Founder & Director notifies of intention to sell stock

Natera, Inc.'s (NASDAQ:NTRA) Intrinsic Value Is Potentially 20% Below Its Share Price

Natera, Inc. Announces New Data from the GALAXY Arm of the Ongoing Circulate-Japan Trial at the 2024 Congress of the European Society for Medical Oncology in Barcelona, Spain

Now 23% overvalued after recent price rise

Consensus estimates of losses per share improve by 20%

Forecast to breakeven in 2026

Co-Founder & Executive Chairman exercised options to buy US$22m worth of stock.

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2026

Natera, Inc. to Report Q2, 2024 Results on Aug 08, 2024

CEO & Director notifies of intention to sell stock

Does Natera (NASDAQ:NTRA) Have A Healthy Balance Sheet?

Natera, Inc. Announces DECIPHER: A Phase II, Single-Arm Adjuvant Trial in Gastroesophageal Cancer

CEO & Director notifies of intention to sell stock

Natera, Inc. Launches Differentiated New Feature for Prospera Heart Test, Enhancing Detection of Rejection for Transplant Patients

Natera: Overdue For A Breather

New minor risk - Insider selling

Secretary & Chief Legal Officer notifies of intention to sell stock

Natera, Inc. (NASDAQ:NTRA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$119

Price target increased by 9.0% to US$113

Natera, Inc. Provides Earnings Guidance for the Year 2024

First quarter 2024 earnings released: US$0.56 loss per share (vs US$1.23 loss in 1Q 2023)

Natera, Inc. to Report Q1, 2024 Results on May 09, 2024

Natera, Inc., Annual General Meeting, Jun 12, 2024

CEO & Director notifies of intention to sell stock

Now 20% undervalued

Natera, Inc. Announces Publication of Larger Prospective dd-cfDNA Study in Kidney Transplantation

Natera, Inc. Announces New Data from Two Studies Extending the Clinical Validation of Its Prospera Heartd-cfDNA Test for Heart Transplant Recipients

Co-Founder & Director notifies of intention to sell stock

Natera, Inc. and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (Modern) A Randomized, Phase Ii/Iii Adjuvant Trial in Urothelial Cancer

Is There An Opportunity With Natera, Inc.'s (NASDAQ:NTRA) 41% Undervaluation?

Natera: Capitalizing On The Positive Momentum Of Personalized Medicine

Natera, Inc. Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™? in Stage II Colorectal Cancer

CEO & Director notifies of intention to sell stock

Consensus estimates of losses per share improve by 11%

Is Natera (NASDAQ:NTRA) A Risky Investment?

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 12% to US$86.94

Natera, Inc. Provides Earnings Guidance for the Year 2024

Natera, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Independent Director notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

Natera, Inc. Announces New Study Demonstrates Signatera's Ability to Risk Stratify and Detect Recurrence Early in Resected Stage I-II Lung Cancer

Co-Founder & Director notifies of intention to sell stock

Natera, Inc. Provides Update on Ravgen Trial

Natera, Inc. Provides Revenue Guidance for the Fourth Quarter and Year Ended December 31, 2023

Natera Announces New Study Highlighting the Benefits of Signatera's Unique Method of Quantifying ctDNA

Estimating The Fair Value Of Natera, Inc. (NASDAQ:NTRA)

Natera, Inc. Presents New Signatera™ MRD Data Across Breast Cancer Treatment Settings at SABCS 2023

Natera, Inc. Raises Revenue Guidance for the Full Year 2023

Is Natera (NASDAQ:NTRA) A Risky Investment?

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Natera, Inc. Announces Randomized, Phase III TREAT ctDNA Trial in Early-Stage Breast Cancer

Natera's RenaCARE Study Demonstrates Significant Diagnostic and Clinical Utility of Renasight in Chronic Kidney Disease

Co-Founder & Director notifies of intention to sell stock

Natera, Inc. Announces Updated Data from the Galaxy Arm of the Circulate-Japan Trial

Natera, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Natera, Inc. to Present New Signatera MRD Data At ESMO 2023, Featuring Large, Updated Analysis from CIRCULATE-Japan Study

Natera, Inc. Announces New MRD Publication in Unresectable Stage I-III Lung Cancer Demonstrates Signatera’s Ability to Risk Stratify and Detect Progression Early

Supreme Court Denies CareDx Request for Appeal in Patent Case with Natera

Natera, Inc. Announces Senior Leadership Appointments

Natera, Inc. Announces Expanded I-Spy 2 Collaboration to Evaluate Signatera™? for Breast Cancer Patients in the Neoadjuvant Setting

Natera, Inc. has completed a Follow-on Equity Offering in the amount of $250.25 million.

Natera, Inc. has completed a Follow-on Equity Offering in the amount of $250.25 million.

Co-Founder & Director notifies of intention to sell stock

Natera's Prospera™ Lung Transplant Assessment Test Granted Medicare Coverage

Natera, Inc. (NASDAQ:NTRA) Shares Could Be 46% Below Their Intrinsic Value Estimate

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Natera, Inc. Revises Earnings Guidance for the Year 2023

Natera Announces Completion of Enrollment to the Randomized, Phase III Altair Trial of Signatera in Colorectal Cancer

Co-Founder & Director notifies of intention to sell stock

United States District Court for the District of Delaware Issues Favorable Ruling for Natera, Inc. in False Advertising Trial Against CareDx, Inc